Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Multiple Sclerosis

• Publication date

  2015-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458514559865PMID 25480857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

  2013cited by this paper
• Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

  2013cited by this paper
• Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies

  2013cited by this paper
• Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis

  2013cited by this paper
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis

  2013cited by this paper
• Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis

  2013cited by this paper
• Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

  2012cited by this paper
• Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique

  2012cited by this paper
• Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

  2012cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

  2009cited by this paper
• observational studies: propensity score analysis of non-randomized data.

  2009cited by this paper
• Drug Class Review: Nasal Corticosteroids

  2008cited by this paper
• Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

  2008cited by this paper
• Toward a Common Framework for Statistical Analysis and Development

  2008cited by this paper
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cited by this paper
• Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

  2007cited by this paper
• Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.

  2007cited by this paper
• Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference

  2007cited by this paper
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cited by this paper
• A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

  2006cited by this paper
• Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing–remitting multiple sclerosis

  2006cited by this paper
• MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis

  2006cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Observational Studies

  2003cited by this paper
• Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

  2002cited by this paper
• Substantial Gains in Bias Reduction from Matching with a Variable Number of Controls

  2000cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Defining the clinical course of multiple sclerosis

  1996cited by this paper
• Reducing Bias in Observational Studies Using Subclassification on the Propensity Score

  1984cited by this paper
• PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

  1965cited by this paper

• A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis

  2025cites this paper
• Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

  2024cites this paper
• Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

  2024cites this paper
• Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

  2022cites this paper
• Therapeutic Advances in Multiple Sclerosis

  2022cites this paper
• Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS

  2021cites this paper
• Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

  2020cites this paper
• Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study

  2020cites this paper
• Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β.

  2019cites this paper
• The MSBase registry: Informing clinical practice

  2019cites this paper
• Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

  2019cites this paper
• Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.

  2019cites this paper
• Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages

  2018cites this paper
• Management of multiple sclerosis patients in central European countries: current needs and potential solutions

  2018cites this paper
• Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience

  2018cites this paper
• Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study.

  2018cites this paper
• A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.

  2018cites this paper
• Real-world-Evidenz

  2017cites this paper
• Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients

  2017cites this paper
• Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

  2017cites this paper
• Peptides Against Autoimmune Neurodegeneration.

  2017cites this paper
• Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data

  2017cites this paper
• Treatment decisions in multiple sclerosis — insights from real-world observational studies

  2017cites this paper
• Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?

  2017cites this paper
• Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies

  2017cites this paper
• Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

  2017cites this paper
• The importance of collecting structured clinical information on multiple sclerosis

  2016cites this paper
• Comparative efficacy of first-line natalizumab vs IFN-&bgr; or glatiramer acetate in relapsing MS

  2016cites this paper
• Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

  2016cites this paper
• Brain health: time matters in multiple sclerosis.

  2016influential citation
• The heritage of glatiramer acetate and its use in multiple sclerosis

  2016cites this paper
• Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.

  2016cites this paper
• Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations

  2016cites this paper
• Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

  2015cites this paper
• Established, new and future disease modifying therapies for MS

  2015cites this paper
• Glatirameracetat oder Interferon-Präparate — was wirkt stärker?

  2015cites this paper
• Established, new and future disease modifying therapies for MS

  2015cites this paper
• Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

  2015cites this paper
• Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies

  2015cites this paper
• Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon

  2015cites this paper
• Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

  2015cites this paper